RxDoctor Payments Data

Mahendra Narendran

Internal Medicine · Statesville, NCNPI 1316074693

Payments from drug & device makers

$17,237in general payments, 2019–2025

Across 1,100 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Pfizer$2K
  • AbbVie$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • plus $9K from 49 others

What the payments were for

  • Food & beverage$17,11199%
  • Education$760%
  • Other$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk135$1,721
AstraZeneca91$1,583
Pfizer101$1,531
AbbVie(2 entities)100$1,353
Boehringer Ingelheim66$1,128
Lilly USA, LLC72$1,087
Amgen63$974
GSK42$645
Johnson & Johnson44$643
Mylan Specialty L.p.29$507
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC32$455
Takeda Pharmaceuticals U.S.A., Inc.25$389
Kowa Pharmaceuticals America, Inc.23$380
Bayer23$355
Ironwood Pharmaceuticals, Inc18$325
Novartis22$300
Idorsia Pharmaceuticals US Inc18$291
Sanofi-aventis U.S. LLC16$268
Abbott13$263
Amarin Pharma, Inc.17$255
Paratek Pharmaceuticals, Inc.17$224
Azurity Pharmaceuticals, Inc.7$196
Astellas Pharma US Inc10$151
Forte Bio-pharma LLC5$147
Biohaven Pharmaceutical Holding Company Ltd.8$145
Exact Sciences8$136
Nestle Healthcare Nutrition Inc.8$128
Axsome Therapeutics, Inc.5$122
Phathom Pharmaceuticals, Inc.7$115
Sunovion Pharmaceuticals Inc.8$114
Ardelyx, Inc.5$112
E.r. Squibb & Sons, L.L.C.7$101
Inspire Medical Systems, Inc.1$100
Genentech USA, Inc.5$92
Sumitomo Pharma America, Inc.4$88
Almatica Pharma LLC5$79
Viatris Specialty LLC4$78
Tolmar, Inc.5$77
Aimmune Therapeutics, Inc.3$67
Supernus Pharmaceuticals, Inc.3$63
Impel Pharmaceuticals Inc.3$62
Verona Pharma, Inc.2$48
Eisai Inc.2$39
Vanda Pharmaceuticals Inc.2$36
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$30
Biohaven Pharmaceuticals, Inc.2$29
Daiichi Sankyo Inc.1$27
Esperion Therapeutics, Inc.1$26
Teva Pharmaceuticals USA, Inc.1$26
Sanofi Pasteur Inc.2$25
Aytu Biopharma, Inc.2$25
Merck2$24
Antares Pharma, Inc.1$20
Hikma Pharmaceuticals USA1$17
Shield Therapeutics Inc1$15

How this compares

$17,237 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$171,147
Medicare patients
321
Services billed
7,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$131,103
JardianceEmpagliflozin120$116,067
EliquisApixaban126$113,130
MounjaroTirzepatide64$82,676
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$77,761
FarxigaDapagliflozin Propanediol46$64,549
XareltoRivaroxaban54$55,201
MyrbetriqMirabegron86$54,933
LinzessLinaclotide66$53,366
Repatha SureclickEvolocumab51$50,434
CreonLipase/Protease/Amylase12$30,896
EntrestoSacubitril/Valsartan20$29,989
TrulicityDulaglutide21$26,104
RybelsusSemaglutide15$24,858
SymbicortBudesonide/Formoterol Fumarate48$17,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,721$155,961125 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$1,128$139,688158 claims
PfizerEliquis$1,531$113,130126 claims
Lilly USA, LLCMounjaro, Trulicity$1,087$108,78085 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$1,583$90,252108 claims
GSKTrelegy Ellipta, Anoro Ellipta$645$90,131127 claims
AbbVieLinzess, Creon, Synthroid$1,353$88,605122 claims
Johnson & JohnsonXarelto$643$55,20154 claims
Astellas Pharma US IncMyrbetriq$151$54,93386 claims
NovartisEntresto$300$29,98920 claims
MerckJanuvia$24$15,72440 claims
Sumitomo Pharma America, Inc.Gemtesa$88$7,47612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →